Information technologySeattle cancer center bets big on experimental T-cell immunotherapy | The Washington Post
The Fred Hutchinson Cancer Researcher Center in Seattle has begun a clinical trial testing CAR T-cell therapy — in which immune cells are removed from the patient, genetically engineered to attack cancer cells and then reinfused — in patients with leukemia and non-Hodgkin lymphoma.
Medical devices and equipmentFDA working to modernize medical device reporting in hospitals | The National Law Review
Recent medical device adverse events prompted FDA to take a fresh look at the ways it collects data related to medical device adverse events from hospitals.
PharmaceuticalsFearing Democratic tidal wave, the drug industry is pouring money into GOP coffers | STAT
With a fight over drug prices expected next year, drug companies have been funneling significant political contributions toward Republican candidates, fearful of what a full Democratic takeover of Washington might mean for the industry, according to a STAT analysis.
Like a pebble skimming the surface of a pond, the decision by Pfizer to end development of an injectable cholesterol treatment has a ripple effect on rivals. The company cited lower effectiveness over time and safety issues, such as higher levels of immunogenicity and reactions patients felt at injection sites. But to what extent is its move a positive or negative for these other drug makers?
Eli Lilly's stock dropped nearly 2 percentage points after Sanders criticized the rising price of the company's Humalog brand insulin, citing a Washington Post report on soaring costs of the diabetes drug.
Safety, quality and clinical practicePremature births rise once again, despite efforts to prevent them | NPR
The number of preterm births in the United States rose in 2015 for the first time in eight years, according to data presented Tuesday by the March of Dimes. Babies born too early face a risk of health complications that can last a lifetime.